Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01758328 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01758328: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01758328 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01758328, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of specialized white cells from the donor at different doses. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein. The protein is called the Wilms' tumor protein, or WT1. The multiple myeloma cells make and express this protein". The investigators want to learn whether the WT1 sensitized T cells will attach to the protein and kill the myeloma cells. The investigators want to find out what effects, good and/or bad, it has on the patient and multiple myeloma.
Interventions
- DRUG fludarabine
- DRUG melphalan
- DRUG busulfan
- BIOLOGICAL anti-thymocyte globulin (ATG)
- PROCEDURE a T cell depleted stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-12 |
| Est. Completion | 2025-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01758328
The ClinicalTrials.gov registry entry for NCT01758328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fludarabine is the first listed.
NCT01758328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01758328 about?
NCT01758328 is a clinical study titled "Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma". The purpose of this study is to test the safety of specialized white cells from the donor at different doses. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein. The protein is called the Wilms' tumor protein, or WT1. The multiple myeloma cell...
What is the current status of trial NCT01758328?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2012-12. Estimated completion is 2025-03-17.
What interventions are being tested in trial NCT01758328?
The interventions under investigation include: fludarabine (DRUG), melphalan (DRUG), busulfan (DRUG), anti-thymocyte globulin (ATG) (BIOLOGICAL), a T cell depleted stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT01758328?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.